- Home
- BDRX vs MTNB Comparison
BDRX vs MTNB Comparison
Compare BDRX & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.29
HOLD
Current Price
$0.80
Company Overview
Basic Information| Metric | BDRX | MTNB |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BDRX | MTNB |
|---|---|---|
| Price | $3.29 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 35.6K |
| Earning Date | 09-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.55 | $0.47 |
| 52 Week High | $92.00 | $3.09 |
Technical Indicators
Market Signals| Indicator | BDRX | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 36.80 |
| Support Level | $4.55 | $0.71 |
| Resistance Level | $7.22 | $0.79 |
| Average True Range (ATR) | 1.51 | 0.10 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 2.09 | 15.41 |
Price Performance
Historical Comparison BDRX
MTNB
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.